Ken Griffin Pacira Bio Sciences, Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 42,000 shares of PCRX stock, worth $998,760. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,000
Previous 18,600
125.81%
Holding current value
$998,760
Previous $444,000
143.69%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding PCRX
# of Institutions
260Shares Held
48.9MCall Options Held
118KPut Options Held
63.7K-
Black Rock Inc. New York, NY8.01MShares$190 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.2MShares$124 Million0.0% of portfolio
-
Doma Perpetual Capital Management LLC Miami, FL2.7MShares$64.2 Million23.38% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.16MShares$51.4 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.14MShares$50.8 Million0.08% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.09B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...